Pharmaceutical companies Biogen and Eisai today (Thursday 21 March) announced they are to discontinue two phase III trials of the Alzheimer's drug aducanumab. The ENGAGE and EMERGE trials were designed to evaluate the efficacy and safety of aducanumab in people with a confirmed diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's disease.
* This article was originally published here
